Akari Therapeutics Plc Sponsored ADR Aktie News

Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for future videos Access the Akari CEO Corner here BOSTON and LONDON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload a...

BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000 of the Company's American Depositary Shares (“ADSs”), each representing 2,000...

BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent applications with the United States Patent and Trademark Office (USPTO). The first application includes claims protecting Akari's novel immuno-oncology...

BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the 40 th Annual SITC Meeting being held November 5-9, 2025 in National Harbor, MD.

Data highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering the Company's antibody drug conjugate (ADC) platform using Akari's spliceoso...

Akari Therapeutics, Plc (NASDAQ:AKTX ) Discusses at Virtual Investor Closing Bell Series Call Company Participants Abizer Gaslightwala - CEO, President & Director Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started.